Endogenous bioactive lipids and the regulation of conventional outflow facility

Expert Review of Ophthalmology

Volumn 3, Issue 4, 2008, Pages 457-470

  Wan, Zhou ^a,c   Woodward, David F ^b   Stamer, W Daniel ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Endocannabinoid; Glaucoma; Intraocular pressure; Lysophospholipid; Outflow facility; Prostaglandin; Prostamide; Schlemm's canal; Trabecular meshwork

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 [4 (1 HYDROXYHEXYL)PHENYL] 5 OXOCYCLOPENTANEHEPTANOIC ACID; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANANDAMIDE; BIMATOPROST; BUNAZOSIN; BUTAPROST; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CAPSAZEPINE; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DEXAMETHASONE; INDOMETACIN; LATANOPROST; LIPID; MATRIX METALLOPROTEINASE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTAMIDE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SULPROSTONE; TIMOLOL; TRAVOPROST; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST;

AQUEOUS HUMOR FLOW; AQUEOUS HUMOR OUTFLOW; CAT; GLAUCOMA; GLAUCOMA SURGERY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LASER SURGERY; MIOSIS; NONHUMAN; PARACRINE SIGNALING; PRIMATE; RABBIT; REVIEW; SCHLEMM CANAL; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK;

EID: 55249105049     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.3.4.457     Document Type: Review

References (139)

1. Leske MC. The epidemiology of open-angle glaucoma: a review. Am. J. Epidemiol. 118(2), 166-191 (1983).
2. Quigley HA. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 80(5), 389-393 (1996).
3. Boland MV, Quigley HA. Risk factors and open-angle glaucoma: classification and application. J. Glaucoma 16(4), 406-418 (2007).
4. Thylefors B, Negrel AD, Pararajasegaram R, Dadzie KY. Global data on blindness. Bull. World Health Organ. 73(1), 115-121 (1995).
5. Clark AF, Yorio T. Ophthalmic drug discovery. Nat. Rev. Drug Discov. 2(6), 448-459 (2003).
6. Grant WM. Clinical measurements of aqueous outflow. AMA Arch. Ophthalmol. 46(2), 113-131 (1951).
7. Lutjen-Drecoll E. Functional morphology of the trabecular meshwork in primate eyes. Prog. Retin. Eye Res. 18(1), 91-119 (1999).
8. Alvarado JA, Yun AJ, Murphy CG. Juxtacanalicular tissue in primary open angle glaucoma and in nonglaucomatous normals. Arch. Ophthalmol. 104(10), 1517-1528 (1986).
9. Lutjen-Drecoll E. Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease. Exp. EyeRes. 81(1), 1-4 (2005).
10. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 363(9422), 1711-1720 (2004).
11. Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog. Retin. Eye Res. 24(5), 612-637 (2005).
12. Rao PV, Shimazaki A, Ichikawa M, Alvarado JA, Epstein DL. Effects of novel ethacrynic acid derivatives on human trabecular meshwork cell shape, actin cytoskeletal organization, and transcellular fluid flow. Biol. Pharm. Bull. 28(12), 2189-2196 (2005).
13. Cai S, Liu X, Glasser A, Volberg T, Filla M, Geiger B et al. Effect of latrunculin-A on morphology and actin-associated adhesions of cultured human trabecular meshwork cells. Mol. Vis. 6132-6143 (2000).
14. Sabanay I, Gabelt BT, Tian B, Kaufman PL, Geiger B. H-7 effects on the structure and fluid conductance of monkey trabecular meshwork. Arch. Ophthalmol. 118(7), 955-962 (2000).
15. Johnson DH. The effect of cytochalasin D on outflow facility and the trabecular meshwork of the human eye in perfusion organ culture. Invest. Ophthalmol. Vis. Sci. 38(13), 2790-2799 (1997).
16. Epstein DL, Rowlette LL, Roberts BC. Acto-myosin drug effects and aqueous outflow function. Invest. Ophthalmol. Vis. Sci. 40(1), 74-81 (1999).
17. Rao PV, Deng P, Sasaki Y, Epstein DL. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility. Exp. Eye Res. 80(2), 197-206 (2005).
18. Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest. Ophthalmol. Vis. Sci. 42(5), 1029-1037 (2001).
19. Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs 21 (3), 167-177 (2007).
20. Kelley MJ, Rose AY, Song K et al. Synergism of TNF and IL-1 in the induction of matrix metalloproteinase-3 in trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 48(6), 2634-2643 (2007).
21. Webb JG, Husain S, Yates PW, Crosson CE. Kinin modulation of conventional outflow facility in the bovine eye. J. Ocul. Pharmacol. Ther. 22(5), 310-316 (2006).
22. Crosson CE, Sloan CF, Yates PW. Modulation of conventional outflow facility by the adenosine A1 agonist N6-cyclohexyladenosine. Invest. Ophthalmol. Vis. Sci. 46(10), 3795-3799 (2005).
23. Bradley JM, Vranka J, Colvis CM et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest. Ophthalmol. Vis. Sci. 39(13), 2649-2658 (1998).
24. Epstein DL, Rohen JW. Morphology of the trabecular meshwork and inner-wall endothelium after cationized ferritin perfusion in the monkey eye. Invest. Ophthalmol. Vis. Sci. 32(1), 160-171 (1991).
25. Ye W, Gong H, Sit A, Johnson M, Freddo TF. Interendothelial junctions in normal human Schlemm's canal respond to changes in pressure. Invest. Ophthalmol. Vis. Sci. 38(12), 2460-2468 (1997).
26. Ethier CR, Chan DW. Cationic ferritin changes outflow facility in human eyes whereas anionic ferritin does not. Invest. Ophthalmol. Vis. Sci. 42(8), 1795-1802 (2001).
27. Johnson M, Chan D, Read AT, Christensen C, Sit A, Ethier CR. The pore density in the inner wall endothelium of Schlemm's canal of glaucomatous eyes. Invest. Ophthalmol. Vis. Sci. 43(9), 2950-2955 (2002).
28. Boldea RC, Roy S, Mermoud A. Ageing of Schlemm's canal in nonglaucomatous subjects. Int. Ophthalmol. 24(2), 67-77 (2001).
29. Ethier CR, Coloma FM, de Kater AW, Allingham RR. Retroperfusion studies of the aqueous outflow system. Part 2: studies in human eyes. Invest. Ophthalmol. Vis. Sci. 36(12), 2466-2475 (1995).
30. Arend KO, Redbrake C. [Update on prospective glaucoma intervention studies]. Klin. Monatsbl. Augenheilkd. 222(10), 807-813 (2005).
31. Nouri-Mahdavi K, Hoffman D, Coleman AL et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 111(9), 1627-1635 (2004).
32. Woodward DF, Gil DW. The inflow and outflow of anti-glaucoma drugs. Trends Pharmacol. Sci. 25(5), 238-241 (2004).
33. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Surv. Ophthalmol. 47(Suppl. 1), S53-S64 (2002).
34. Wan Z, Woodward DF, Cornell CL et al. Bimatoprost, prosta-mide activity, and conventional drainage. Invest. Ophthalmol. Vis. Sci. 48(9), 4107-4115 (2007).
35. Bahler CK, Howell KG, Hann CR, Fautsch MP. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am. J. Ophthalmol. 145(1), 114-119 (2008).
36. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 α analog, on aqueous humor dynamics in human eyes. Ophthalmology 100(9), 1297-1304 (1993).
37. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 α analogue, after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol. 111(10), 1351-1358 (1993).
38. Stjernschantz JW. From PGF(2α)- isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Invest. Ophthalmol. Vis. Sci. 42(6), 1134-1145 (2001).
39. Toris CB, Zhan G, Fan S et al. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J. Glaucoma 16(2), 189-195 (2007).
40. Christiansen GA, Nau CB, McLaren JW, Johnson DH. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 111(9), 1658-1662 (2004).
41. Goh Y, Urade Y, Fujimoto N, Hayaishi O. Content and formation of prostaglandins and distribution of prostaglandin-related enzyme activities in the rat ocular system. Biochim. Biophys. Acta. 921(2), 302-311 (1987).
42. Weinreb RN, Mitchell MD, Polansky JR, Prostaglandin production by human trabecular cells: in vitro inhibition by dexamethasone. Invest. Ophthalmol. Vis. Sci. 24(12), 1541-1545 (1983).
43. el-Shabrawi Y, Eckhardt M, Berghold A et al. Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone. Eye 14(Pt 3A), 375-383 (2000).
44. Zhan GL, Toris CB, Camras CB, Wang YL, Yablonski ME. Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow. J. Ocul. Pharmacol. Ther. 14(3), 217-228 (1998).
45. Gilabert R, Gasull X, Pales J, Belmonte C, Bergamini MV, Gual A. Facility changes mediated by cAMP in the bovine anterior segment in vitro. Vision Res. 37(1), 9-15 (1997).
46. Crawford KS, Gange SJ, Gabelt BT et al. Indomethacin and epinephrine effects on outflow facility and cyclic adenosine monophosphate formation in monkeys. Invest. Ophthalmol. Vis. Sci. 37(7), 1348-1359 (1996).
47. Polansky JR, Kurtz RM, Alvarado JA, Weinreb RN, Mitchell MD. Eicosanoid production and glucocorticoid regulatory mechanisms in cultured human trabecular meshwork cells. Prog. Clin. Biol. Res. 312113-138 (1989).
48. 2 on aqueous humor dynamics in monkeys. Arch. Ophthalmol. 116(9), 1213-1216 (1998).
49. 2 0.1% on intraocular pressure in laser-induced glancomatous monkey eyes. J. Glaucoma 10(3), 215-219 (2001).
50. Gabelt BT, Seeman JL, Podos SM, Mittag TW, Kaufman PL. Aqueous humor dynamics in monkeys after topical 8-iso PGE(2). Invest Ophthalmol. Vis. Sci. 45(3), 892-899 (2004).
51. Bhattacherjee P, Williams BS, Paterson CA. Responses of intraocular pressure and the pupil of feline eyes to prostaglandin EP1 and FP receptor agonists. Invest. Ophthalmol. Vis. Sci. 40(12), 3047-3053 (1999).
52. Krauss AH, Woodward DF, Chen J et al. AGN 191976: a novel thromboxane A2-mimetic with ocular hypotensive properties. J. Ocul. Pharmacol. Ther. 11(3), 203-212 (1995).
53. 2, FP, or TP prostanoid-receptor stimulation may reduce intraocular pressure. Invest. Ophthalmol. Vis. Sci. 31(12), 2560-2567 (1990).
54. Woodward DF, Burke JA, Williams LS et al. Prostaglandin F2 α effects on intraocular pressure negatively correlate with FP-receptor stimulation. Invest Ophthalmol. Vis. Sci. 30(8), 1838-1842 (1989).
55. Richter M, Krauss AH, Woodward DF, Lutjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest. Ophthalmol. Vis. Sci. 44(10), 4419-4426 (2003).
56. 2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest. Ophthalmol. Vis. Sci. 47(9), 4042-4049 (2006).
57. 4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow (In press).
58. Kamphuis W, Schneemann A, Shichi H, Broersma L, Hoyng PF. Immunolocalization of prostanoid EP receptor isorypes in human trabecular meshwork. Curr. Eye Res. 29(1), 17-26 (2004).
59. Kamphuis W, Schneemann A, van Beek LM, Smit AB, Hoyng PF, Koya E. Prostanoid receptor gene expression profile in human trabecular meshwork: a quantitative real-time PCR approach. Invest. Ophthalmol. Vis. Sci. 42(13), 3209-3215 (2001).
60. Schlotzer-Schrehardt U, Zenkel M, Nusing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest. Ophthalmol. Vis. Sci. 43(5), 1475-1487 (2002).
61. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu. Rev. Pharmacol. Toxicol. 41661-41690 (2001).
62. 2. J. Biol. Chem. 277(4), 2614-2619 (2002).
63. Liang Y, Li C, Guzman VM, Chang WW et al. Upregulation of orphan nuclear receptor Nur77 following PGF(2α), Bimatoprost, and Butaprost treatments. Essential role ofa protein kinase C pathway involved in EP(2) receptor activated Nur77 gene transcription. Br. J. Pharmacol. 142(4), 737-748 (2004).
64. Dijkstra BG, Schneemann A, Hoyng PF. Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest. Ophthalmol. Vis. Sci. 40(11), 2622-2626 (1999).
65. Schneemann A, Hoyng PF, Kamphuis W. Effects of elevated pressure on prostanoid receptor gene expression levels in human trabecular meshwork. Ophthalmic. Res. 34(5), 314-318 (2002).
66. Krauss AH, Wiederholt M, Sturm A, Woodward DF. Prostaglandin effects on the contractility of bovine trabecular meshwork and ciliary musde. Exp. Eye Res. 64(3), 447-453 (1997).
67. 2) receptors opens BKCa channels and relaxes ocular trabecular meshwork. Exp. Eye Res. 80(5), 697-708 (2005).
68. Kaddour-Djebbar I, Ansari HR, Akhtar RA, Abdel-Latif AA. Species differences in the effects of prostanoids on MAP kinase phosphorylation, myosin light chain phosphorylation and contraction in bovine and cat iris sphincter smooth muscle. Prostaglandins Leukot. Essent. Fatty Acids 72(l), 49-57 (2005).
69. 2 agonist) on Cyr61 and connective tissue growth factor gene expression. J. Biol. Chem. 278(29), 27267-27277 (2003).
70. Lindsey JD, Kashiwagi K, Boyle D, Kashiwagi F, Firestein GS, Weinreb RN. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr. Eye Res. 15(8), 869-875 (1996).
71. Pang IH, Hellberg PE, Fleenor DL, Jacobson N, Clark AF. Expression of matrix metalloproteinases and their inhibitors in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 44(8), 3485-3493 (2003).
72. Parshley DE, Bradley JM, Fisk A et al. Laser trabeculoplasty induces stromelysin expression by trabecular juxtacanalicular cells. Invest. Ophthalmol. Vis. Sci. 37(5), 795-804 (1996).
73. Anthony TL, Pierce KL, Stamer WD, Regan JW. Prostaglandin F2 α receptors in the human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 39(2), 315-321 (1998).
74. Thieme H, Schimmat C, Munzer G et al. Endothelin antagonism: effects of FP receptor agonists prostaglandin F2α and fluprostenol on trabecular meshwork contractility. Invest. Ophthalmol. Vis. Sci. 47(3), 938-945 (2006).
75. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveosderal outflow. Surv. Ophthalmol. 41(Suppl. 2), S53-S59 (1997).
76. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp. Eye Res. 67(2), 179-191 (1998).
77. Oh DJ, Martin JL, Williams AJ, Russell P, Birk DE, Rhee DJ. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 47(9), 3887-3895 (2006).
78. Weinreb RN, Lindsey JD, Marchenko G, Marchenko N, Angert M, Strongin A. Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest. Ophthalmol. Vis. Sci. 45(12), 4368-4377 (2004).
79. Gaton DD, Sagara T, Lindsey JD, Cabelt BT, Kaufman PL, Weinreb RN. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 α)-isopropyl ester treatment. Arch. Ophthalmol. 119(8), 1165-1170 (2001).
80. Weinreb RN. Enhancement ofsderal macromolecular permeability with prostaglandins. Trans. Am. Ophthalmol. Soc. 99319-99343 (2001).
81. Hinz B, Rosch S, Ramer R, Tamm ER, Brune K. Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism. Faseb. J. 19(13), 1929-1931 (2005).
82. Husain S, Abdel-Latif AA. Effects of prostaglandin F(2α)and carbachol on MAP kinases, cytosolic phospholipase A(2)and arachidonic acid release in cat iris sphincter smooth musde cells. Exp. Eye Res. 72(5), 581-590 (2001).
83. Husain S, Jafri F, Crosson CE. Acute effects of PGF2α on MMP-2 secretion from human ciliary muscle cells: a PKC- and ERK-dependent process. Invest. Ophthalmol. Vis. Sci. 46(5), 1706-1713 (2005).
84. Lindsey JD, To HD, Weinreb RN. Induction of c-fos by prostaglandin F2 α in human ciliary smooth muscle cells. Invest. Ophthalmol. Vis. Sci. 35, 242-250 (1994).
85. Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog. Retin. Eye Res. 19(3), 271-295 (2000).
86. Thieme H, Steinhausen K, Ottlecz A, Lambrou GN, Strauss O, Wiederholt M et al. Effects of unoprostone and endothelin 1 on L-type channel currents in human trabecular meshwork cells. Ophthalmic. Res. 37(6), 293-300 (2005).
87. Thieme H, Stumpff F, Ottlecz A, Percicot CL, Lambrou GN, Wiederholt M. Mechanisms of action of unoprostone on trabecular meshwork contractility. Invest. Ophthalmol. Vis. Sci. 42(13), 3193-3201 (2001).
88. Kozak KR, Crews BC, Morrow JD et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacydin glycerol esters and ethanolamides. J. Biol. Chem. 277, 44877-44885 (2002).
89. Matias I, Chen J, De Petrocellis L et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J. Pharmacol. Exp. Ther. 309(2), 745-757 (2004).
90. Spada CS, Krauss AH, Woodward DF, Chen J, Protzman CE, Nieves AL et al. Bimatoprost and prostaglandin F(2 α) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells. Exp. Eye Res. 80(1), 135-145 (2005).
91. Chen J, Senior J, Marshall K et al. Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles. Br. J. Pharmacol. 144(4), 493-501 (2005).
92. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 110(3), 609-614 (2003).
93. Zhao X, Pearson KE, Stephan DA, Russell P. Effects of prostaglandin analogues on human ciliary muscle and trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 44(5), 1945-1952 (2003).
94. Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest. Ophthalmol. Vis. Sci. 44(2), 715-721 (2003).
95. Davies SS, Ju WK, Neufeld AH, Abran D, Chemtob S, Roberts LJ, 2nd. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J. Ocul. Pharmacol. Ther. 19(1), 45-54 (2003).
96. Krauss AH, Woodward DF. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv. Ophthalmol. 49(Suppl. 1), S5-Sll (2004).
97. Woodward DF, Krauss AH, Chen J et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J. Pharmacol. Exp. Ther. 305(2), 772-785 (2003).
98. Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br. J. Pharmacol. (2007).
99. Woodward DF, Krauss AH, Wang JW et al. Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris. Br. J. Pharmacol. 150(3), 342-352 (2007).
100. Helper RS, Frank IM. Marihuana smoking and intraocular pressure. J. Am. Med. Assoc. 217, 1392 (1971).
101. Devane WA, Hanus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258(5090), 1946-1949 (1992).
102. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441), 61-65 (1993).
103. Howlett AC, Qualy JM, Khachatrian LL. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. 29(3), 307-313 (1986).
104. Wartmann M, Campbell D, Subramanian A, Burstein SH, Davis RJ. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett. 359(2-3), 133-136 (1995).
105. Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annu. Rev. Pharmacol. Toxicol. 38179-38200 (1998).
106. Stamer WD, Golightly SF, Hosohata Y et al. Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur. J. Pharmacol. 431 (3), 277-286 (2001).
107. Bisogno T, Ligresti A, Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol. Biochem. Behav. 81(2), 224-238 (2005).
108. Straiker AJ, Maguire G, Mackie K, Lindsey J. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest. Ophthalmol. Vis. Sci. 40(10), 2442-2448 (1999).
109. Zhong L, Geng L, Njie Y, Feng W, Song ZH. CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility. Invest. Ophthalmol. Vis. Sci. 46(6), 1988-1992 (2005).
110. Wright K, Rooney N, Feeney M et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129(2), 437-453 (2005).
111. Lamontagne D, Lepicier P, Lagneux C, Bouchard JF. The endogenous cardiac cannabinoid system: a new protective mechanism against myocardial ischemia. Arch. Mal. Coeur Vaiss. 99(3), 242-246 (2006).
112. Laine K, Jarvinen K, Mechoulam R, Breuer A, Jarvinen T. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest. Ophthalmol. Vis. Sci. 43(10), 3216-3222 (2002).
113. Matsuda S, Kanemitsu N, Nakamura A al. Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues. Exp. Eye Res. 64(5), 707-711 (1997).
114. Bisogno T, Delton-Vandenbroucke I, Milone A, Lagarde M, Di Marzo V. Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. Arch. Biochem. Biophys. 370(2), 300-307 (1999).
115. Chen J, Matias I, Dinh T et al. Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem. Biophys. Res. Commun. 330(4), 1062-1067 (2005).
116. Chien FY, Wang RF, Mittag TW, Podos SM. Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Arch. Ophthalmol. 121(1), 87-90 (2003).
117. Song ZH, Slowey CA. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. J. Pharmacol. Exp. Ther. 292(1), 136-139 (2000).
118. Pate DW, Jarvinen K, Urtti A et al. Effects of topical anandamides on intraocular pressure in normotensive rabbits. Life Sci. 58(21), 1849-1860 (1996).
119. Pate DW, Jarvinen K, Urtti A, Jarho P, Jarvinen T. Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Curr.. Eye Res. 14(9), 791-797 (1995).
120. Porcella A, Maxia C, Gessa GL, Pani L. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur. J. Neurosci. 13(2), 409-412 (2001).
121. Kumar A, Song ZH. CB1 cannabinoid receptor-mediated changes of trabecular meshwork cellular properties. Mol. Vis. 12290-12297 (2006).
122. Njie YF, Kumar A, Qiao Z, Zhong L, Song ZH. Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. Invest. Ophthalmol. Vis. Sci. 47(5), 1999-2005 (2006).
123. He F, Song ZH. Molecular and cellular changes induced by the activation of CB2 cannabinoid receptors in trabecular meshwork cells. Mol. Vis. 131348-1356 (2007).
124. Rosch S, Ramer R, Brune K, Hinz B. R(+)-methanandamide and other cannabinoids induce the expression of cyclooxygenase-2 and matrix metalloproteinases in human nonpigmented ciliary epithelial cells. J. Pharmacol. Exp. Ther. 316(3), 1219-1228 (2006).
125. Laine K, Jarvinen T, Savinainen J, Laitinen JT, Pate DW, Jarvinen K. Effects of topical anandamide-transport inhibitors, AM404 and olvanil, on intraocular pressure in normotensive rabbits. Pharm Res. 18(4), 494-499 (2001).
126. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther. 115(1), 84-105 (2007).
127. Panetti TS. Differential effects of sphingosine 1-phosphate and lysophosphatidic acid on endothelial cells. Biochim. Biophys. Acta. 1582(1-3), 190-196 (2002).
128. Liliom K, Guan Z, Tseng JL, Desiderio DM, Tigyi G, Watsky MA. Growth factor-like phospholipids generated after corneal injury. Am. J. Physiol. 274(4 Pt 1), C1065-C1074 (1998).
129. Mettu PS, Deng PF, Misra UK, Gawdi G, Epstein DL, Rao PV. Role of lysophospholipid growth factors in the modulation of aqueous humor outflow facility. Invest. Ophthalmol. Vis. Sci. 45(7), 2263-2271 (2004).
130. Sumida GM, Read AT, Perkumas KM, Stamer WD, Ethier CR. S1P Receptor mediated effects on outflow facility of human eyes in organ culture. ARVO. 3927, (2007).
131. Dudek SM, Jacobson JR, Chiang ET et al. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J. Biol. Chem. 279(23), 24692-24700 (2004).
132. Shikata Y, Birukov KG, Garda JG. SlP induces FA remodeling in human pulmonary endothelial cells: role ofRac, GIT1, FAK, and paxillin. J. Appl. Physiol. 94(3), 1193-1203 (2003).
133. Garcia JG, Liu F, Verin AD, Birukova A et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg- dependent cytoskeletal rearrangement. J. Clin. Invest. 108(5), 689-701 (2001).
134. Tan JC, Peters DM, Kaufman PL. Recent developments in understanding the pathophysiology of elevated intraocular pressure. Curr. Opin. Ophthalmol. 17(2), 168-174 (2006).
135. Thieme H, Nass JU, Nuskovski M et al. The effects of protein kinase C on trabecular meshwork and ciliary muscle contractility. Invest. Ophthalmol. Vis. Sci. 40(13), 3254-3261 (1999).
136. Sanka K, Maddala R, Epstein DL, Rao PV. Influence of actin cytoskeletal integrity on matrix metalloproteinase-2 activation in cultured human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 48(5), 2105-2114 (2007).
137. 2+-dependent, but MAPK-independent mechanism in rat vascular smooth musde cells. Life Sci. 80(19), 1768-1776 (2007).
138. Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S et al. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. Mol. Pharmacol. 70(1), 41-50 (2006).
139. Chiba T, Kashiwagi K, Chiba N, Tsukahara S. Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br. J. Ophthalmol. 90(3), 314-317 (2006).